

ESMO 2016 PRESS CONFERENCE PROGRAMME*

<p>Friday, 7 October 10:30-11:30</p> <p>Moderator: Solange Peters</p>	<p>Prof Solange Peters, Chair ESMO Press Committee: Overview of ESMO Press Programme Prof Ulrik Lassen, ESMO Local Officer Denmark Prof Andrés Cervantes, Chair ESMO 2016 Scientific Programme: Scientific Programme Highlights Dr Lidija Kandolf-Sekulovic: 13890_PR < 5000 patients denied access to new, life-saving drugs every year in Europe Prof Josep Taberero, ESMO President Elect: ESMO initiatives for equal access to treatment Prof Fortunato Ciardiello, ESMO President: ESMO vision for integrated care Prof Solange Peters: Q&A</p>
<p>Saturday, 8 October 2016 08:15-09:00</p> <p>Moderator: Evandro De Azambuja</p>	<p>LBA1_PR: First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC). Monaleesa 2. <i>Gabriel Hortobagyi</i></p> <p>LBA2_PR: Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial. <i>Alexander Eggermont</i></p> <p>LBA3_PR: A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial). <i>Mansoor Raza Mirza</i></p>
<p>Sunday, 9 October 2016 08:15-09:00</p> <p>Moderator: Stefan Zimmermann</p>	<p>LBA8_PR: KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) $\geq 50\%$. <i>Martin Reck</i></p> <p>LBA42_PR: Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): results from the confirmatory phase 3 ASCEND-5 study. <i>Giorgio Scagliotti</i></p> <p>LBA44_PR: Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC. <i>Fabrice Barlesi</i></p> <p>LBA 2949_PR: Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: Keynote-021 cohort g. <i>Corey Langer</i></p>

<p>Monday, 10 October 08:15-09:00</p> <p>Moderator: Dirk Arnold</p>	<p>LBA9_PR: Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). <i>Karim Fizazi</i></p> <p>LBA11_PR: Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC) Alain <i>Ravaud</i></p> <p>LBA30_PR: CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. <i>Toni Choueiri</i></p> <p>LBA6_PR: Full-dose neoadjuvant anthracycline+ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. <i>Alessandro Gronchi</i></p>
<p>Tuesday, 11 October 08:15-9:00</p> <p>Congress highlights Q&A for Press</p>	<p>Prof Solange Peters, Chair ESMO Press Committee</p> <p>Prof Andrés Cervantes, Chair ESMO 2016 Scientific Programme</p>

*Subject to changes